Amsterdam’s Avanzanite secures €32M to scale rare-disease treatments across Europe

Amsterdam’s Avanzanite raises €32M to support its expansion across Europe and strengthen its work with rare-disease medicines.

Amsterdam-based Avanzanite Bioscience BV, a company that develops and distributes treatments for rare diseases, has raised €32M in a Series A round of funding. 

The investment came from MVM Partners, a global life-science private equity firm.

MVM has invested in healthcare businesses since 1997. Its teams in Boston, London, and the San Francisco Bay Area focus on opportunities across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors.

MVM’s commitment of up to €32M came from its €500M sixth fund. The firm has also set aside more capital to support later stages of Avanzanite’s expansion. MVM is the first investor that represents institutions to join Avanzanite and will take a seat on the company’s Board of Directors.

Dr. Jack Tanaka, Partner at MVM, says, “For years, MVM has watched promising rare disease medicines struggle to find a path to patients – Avanzanite breaks this pattern.”

“In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.”

Capital utilisation

The funds will support the expansion of Avanzanite’s operations across Europe and advance both current and upcoming launches of rare disease products. 

The capital will also allow the company to pursue new strategic partnerships and acquire assets that add to its portfolio.

Adam Plich, founder and CEO of Avanzanite, says, “We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite.”

“With MVM’s support, we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey.”

Transforming the orphan drug landscape

Founded in 2022 by Adam Plich and Anant Murthy, Avanzanite works with biotech and pharmaceutical firms to introduce orphan medicines across European markets. 

The company aims to close gaps in access to rare-disease treatments and to help innovators achieve full reach for their products across the region.

Avanzanite operates through a single Europe-wide structure that covers market access, pricing, reimbursement, and other commercial functions. This structure is designed to support companies that face limits with standard launch approaches and to help bring rare-disease medicines to patients in all 32 European markets.

Since its inception, the company has formed three alliances with industry partners. Its current portfolio includes three medicines in nephrology, ophthalmology, and haematology, with licensing or distribution rights in the European Economic Area, the United Kingdom, and Switzerland.

Avanzanite reported its highest Q3 results in 2025, with revenue reaching three times the level of the same period in the previous year and rising more than 20 per cent from the prior quarter.